Close Menu

NEW YORK – The Centers for Medicare & Medicaid Services will now cover Myriad Genetics' BRACAnalysis CDx when used to identify prostate cancer patients with germline BRCA1 and BRCA2 mutations who may benefit from the PARP inhibitor olaparib (AstraZeneca/Merck's Lynparza), the company said on Friday.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.